Project regional focus: Actively operating in the United States (49 states)
The problem
The U.S. healthcare system is built for acute care rather than preventive monitoring. This means:
- ~50% of patients miss the annual blood tests they need
- Traditional laboratories require appointments, travel, and waiting — while remaining expensive for patients
- At-home blood testing is largely inaccessible — samples are unstable and accuracy is low
- Preventive diagnostics is growing 3× faster than clinical laboratory infrastructure, yet the technology platform for it has not yet been built
- Chronic diseases (cardiovascular conditions, diabetes, kidney failure) reduce healthy years of life, while most are diagnosed too late. The company is building infrastructure that enables earlier detection of these conditions — at the scale of entire populations.
Solution and product
A fully integrated preventive blood testing platform combining:
- An at-home blood collection device (fingerstick or upper-arm lancet) with sample stability of up to 6 weeks and hospital-grade accuracy
- A proprietary CLIA/CAP-certified laboratory operating across 49 states with unique IP-based processing methods
- A white-label platform for sponsors: campaign analytics, KPIs, and communication templates
- A mobile interface for patients: AI chat for sample collection, QR activation, multilingual support, and a results portal
- A biomarker panel including Lp(a), ApoB, LDL-C, hs-CRP, eGFR, and HbA1c — with expansion into hormones, metabolic health, and cardiovascular markers
- A white-labelable and white-brandable product: the client receives a fully customized solution under its own brand, with launch possible within 1–2 weeks.
Brief market overview
Preventive healthcare is one of the most structurally fast-growing segments in healthcare:
- The market is expected to exceed $0.5 trillion by 2030, with an estimated CAGR of ~12% (versus ~4% for traditional laboratories)
- Two flagship healthtech IPOs in 2025 confirmed market appetite for preventive technologies
- Sponsors (pharma, insurers, NGOs) are increasingly seeking white-label platforms with analytics and conversion capabilities
- New York State approval is a real barrier to entry for competitors; Endless is already approaching this milestone
Tangible and intangible assets
- Proprietary blood collection and processing technology (3 pending patents)
- A CLIA/CAP-certified laboratory operating across 49 states, with its own LIMS system (reducing friction in scaling)
- A white-label platform for sponsors
- A data moat: 125K+ tests with longitudinal data from underserved populations
Current project stage and achievements
- The company is demonstrating rapid growth: $3M+ annual revenue run-rate as of Q2 2026, with 125,000+ tests completed across 49 U.S. states
- 310% year-over-year revenue growth (~40% MoM over the past 6 months)
- NPS 80+ (versus -30 for LabCorp/Quest)
- Kit return rate of ~50% (versus <25% across the industry and 10% for Cologuard)
- 100% client retention — all partners renewed their contracts for a third year, doubling volumes
Team and personnel
The company was founded by entrepreneurs and executives with backgrounds in medicine, technology, and business. Key team members have experience at: Stanford Medicine and McKinsey; Apple (inventor of the Health App and EKG on Apple Watch); Foundation Medicine (scaled through IPO and acquisition by Roche); CLIA laboratories (20+ years in blood testing technology development); Harvard; and Northeastern.
Core current and target project metrics
- $3M+ annual revenue run-rate (Q2 2026)
- 125K+ tests across 49 states
- 310% YoY growth
- NPS 80+
- Kit return rate ~50%
- Gross margin of 65–70%
Unit economics:
- Strong 65–70% margins across both business lines (platform + laboratory)
- 100% client retention with volumes doubling annually
Target metrics (12–24 months):
- $6M+ ARR by the end of 2026
- $24M ARR by the end of 2027
- ~$100M revenue run-rate by 2029
- Expansion of the test menu to 80 biomarkers
- New York State approval and preparation for FDA approval
Investor offering
A venture-type investment structure under which returns are generated exclusively through growth in the company’s valuation and the subsequent sale of ICLUB’s stake, with no dividend distributions.
Minimum ticket: USD 5,000 / venture model (return through valuation growth).
Timeline: deadline April 28, 2026
Exit opportunities
- Sale to a strategic player (healthtech)
- Subsequent funding rounds at a higher valuation
- Consolidation of the digital healthcare market
The potential valuation increase in the next round is expected to be multiple times the current level.
Additional information about the project is available after registration in the app via the link.
Join the closed Telegram chat to learn about other current investment opportunities: https://t.me/+qNeq1Ir3irZhMTBi
